Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05890781
Recruiting Not applicable

Engineering Immune Organoids to Study Pediatric Cancer

NCT05890781 · tracked via the Priya Life Science France tracker
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Not applicable
Started
2023-05-12
Last updated
2026-02-09

Condition(s) studied

Brain TumorKidney TumorNeuroblastomaSarcoma

Investigational drug(s) / intervention(s)

Skin biopsyFresh tumor sampleBlood sample →Healthy tissue from the tumorSpinal cerebrospinal fluid (SCF)

Skin biopsy: Skin biopsy

Fresh tumor sample: Fresh tumor sample

Blood sample: Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

Healthy tissue from the tumor: Healthy tissue from the tumor site whenever possible

Spinal cerebrospinal fluid (SCF): Spinal cerebrospinal fluid (SCF) whenever possible

Study summary

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Eligibility

Sex
ALL
Min age
—
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision

Primary outcome measure(s)

  • Proportion of viable and exploitable immune organoids with engrafted tumor cells — until 5 years after enrolment

Trial sites (2)

FacilityCityRegionStatus
Gustave Roussy Villejuif France Recruiting
Hopital Necker Paris Île-de-France Region Recruiting

More Gustave Roussy, Cancer Campus, Grand Paris trials in France

IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas Recruiting
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma Recruiting
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer Recruiting
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Recruiting
Cohort of Patients With Chronic Myelomonocytic Leukemia Recruiting

Other trials for the same condition

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) Recruiting
Establishment of a Prospective Clinical-biological Database Recruiting
Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma Recruiting
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) Active, not recruiting
Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05890781 on ClinicalTrials.gov ↗ ← All trials in France